JW Pharmaceutical announced on the 7th through a provisional performance disclosure that its sales for the first quarter based on separate financial statements amounted to 183.5 billion won, a 3% increase compared to the same period last year. During the same period, operating profit decreased by 15.4%, recording 22.6 billion won. The company explained that this was due to increased research and development (R&D) expenses. The company's operating profit margin for the first quarter is 12.3%. Net profit for the period decreased by 11.8% to 17.5 billion won compared to the same period last year.
Sales in the institutional sector of prescription pharmaceuticals reached 152.2 billion won, marking a 6.2% increase compared to the same period last year. The hyperlipidemia treatment drug "Rivarojet" achieved sales of 23.4 billion won, demonstrating a high growth rate of 35.1%, while the entire Rivaro product line, including "Rivaro," recorded sales of 45.5 billion won, up 18.4%.
Sales of the hemophilia treatment drug "Hemlibra" and the rheumatoid arthritis treatment drug "Actemra" were 14.5 billion won and 6 billion won, respectively, marking increases of 29.2% and 16.7% compared to the same period last year. The intravenous solutions sector reported sales of 60.4 billion won, reflecting a 1.5% increase over the first quarter of last year.
Sales of the high-value-added comprehensive nutritional intravenous solution product line "Winnerf" increased by 11.6% year-on-year to 20.2 billion won. Sales of basic intravenous solutions for the same period rose by 7.3%, totaling 20.7 billion won.
A JW Pharmaceutical representative noted, "Key original prescription drugs such as Rivarojet and Hemlibra are showing continuous growth, driving overall performance," and added, "We will continue to expand investment in innovative drug development projects following a mid- to long-term growth strategy centered on R&D."